Novo Nordisk sees profit boost from U.S. sales adjustments, faces impairments By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2025
0mins
Source: Investing.com
Financial Performance: Novo Nordisk reported a 25% increase in operating profit for 2024, reaching DKK 128.3 billion, driven by strong sales in diabetes and obesity care, particularly from GLP-1 treatments, while net profit rose by 21% to DKK 100.9 billion.
Future Outlook: The company anticipates sales growth of 16% to 24% in 2025, with potential challenges including competition and supply constraints, while planning to propose a 21% increase in dividends at the upcoming Annual General Meeting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
